

Personalised Cancer Medicine Flashcards 2025

Colorectal Cancer



Standard

Microsatellite Instability
Study (MSI-H, dMMR)*
KRAS, NRAS
BRAF
DPD

* by IHC (MLH1, PMS2, MSH2 and MSH6) or genetic study (BAT25 and BAT26, D2S123, D5S346 and D17S250).

Recommended

NTRK*
HER2**

* in tumors with microsatellite instability, M1G1 hypermethylation and RAS wild type (IHC + FISH, NGS, RT-PCR, NanoString)
**(IHC or FISH or NGS) en RAS y BRAF WT

Currently not recommended

Immunoscore
CMS classification
MET
EGFR
FGFR
PI3K

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System

The **Recommended** category is based on current recommendations by EMEA and FDA

1. García-Alfonso P, García-Carbonero R, García-Foncillas J, et al. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2020 Nov;22(11):1976-1991. doi: 10.1007/s12094-020-02357-z.
2. Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol. 2021 Aug;18(8):506-525. doi: 10.1038/s41571-021-00495-z
3. Ros J, Vaghi C, Baraibar I, Saoudi González N, Rodríguez-Castells M, García A, Alcaraz A, Salva F, Tabernero J, Elez E. Targeting KRASG12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. Int J Mol Sci. 2024 Mar 14;25(6):3304. doi: 10.3390/ijms25063304. PMID: 38542278; PMCID: PMC10970443.



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

